Fairvoy Private Wealth LLC Raises Holdings in Axon Enterprise, Inc $AXON

Fairvoy Private Wealth LLC boosted its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 2.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,710 shares of the biotechnology company’s stock after purchasing an additional 60 shares during the quarter. Fairvoy Private Wealth LLC’s holdings in Axon Enterprise were worth $2,244,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Jennison Associates LLC increased its holdings in shares of Axon Enterprise by 23,203.7% in the 1st quarter. Jennison Associates LLC now owns 614,053 shares of the biotechnology company’s stock valued at $322,961,000 after acquiring an additional 611,418 shares during the last quarter. Nuveen LLC purchased a new position in shares of Axon Enterprise in the 1st quarter valued at about $264,796,000. Westfield Capital Management Co. LP increased its holdings in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company’s stock valued at $487,977,000 after acquiring an additional 212,931 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company’s stock valued at $4,540,005,000 after acquiring an additional 185,571 shares during the last quarter. Finally, Axiom Investors LLC DE purchased a new position in shares of Axon Enterprise in the 1st quarter valued at about $93,088,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Stock Down 0.7%

Shares of NASDAQ AXON opened at $715.51 on Friday. The stock has a market cap of $56.17 billion, a PE ratio of 176.67, a price-to-earnings-growth ratio of 27.98 and a beta of 1.41. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52-week low of $413.68 and a 52-week high of $885.91. The business has a 50-day moving average price of $757.79 and a 200 day moving average price of $707.36.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same period last year, the firm earned $1.20 EPS. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AXON. Bank of America increased their price objective on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Wolfe Research began coverage on Axon Enterprise in a report on Monday, July 7th. They issued an “outperform” rating on the stock. Craig Hallum upgraded Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a report on Tuesday, August 5th. Northland Securities set a $800.00 price objective on Axon Enterprise in a report on Tuesday, August 5th. Finally, JMP Securities reissued a “market outperform” rating and issued a $825.00 target price on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $841.64.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the completion of the sale, the director directly owned 1,416 shares of the company’s stock, valued at approximately $1,065,596.64. This trade represents a 6.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,932 shares of company stock worth $37,978,216 in the last ninety days. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.